Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial
NewAmsterdam Pharma
Ashish Sarraju; Danielle Brennan; Kierstyn Hayden; Amanda Stronczek; Anne C Goldberg; Erin D Michos; Darren K McGuire; Denise Mason; Grace Tercek; Stephen J Nicholls; Douglas Kling; Annie L Neild; John Kastelein; Michael Davidson; Marc Ditmarsch; Steven E Nissen